First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.07 USD 3.56% Market Closed
Updated: Apr 28, 2024

Aquestive Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Operating Income
-$15.1m
CAGR 3-Years
29%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$23.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.8B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Operating Income
$4.1B
CAGR 3-Years
-28%
CAGR 5-Years
-19%
CAGR 10-Years
-7%
Eli Lilly and Co
NYSE:LLY
Operating Income
$10.3B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
6%

See Also

What is Aquestive Therapeutics Inc's Operating Income?
Operating Income
-15.1m USD

Based on the financial report for Dec 31, 2023, Aquestive Therapeutics Inc's Operating Income amounts to -15.1m USD.

What is Aquestive Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
21%

Over the last year, the Operating Income growth was 64%. The average annual Operating Income growth rates for Aquestive Therapeutics Inc have been 29% over the past three years , 21% over the past five years .